Bio-Techne Corp splits its revenue into 5 lines in its filings. The largest line in Q4 of fiscal 2026, the quarter ended Jun 30, 2026 was Consumables at $260.7 million, 81% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q4 FY2026
Jun 30, 2026
|
Q3 FY2026
Mar 31, 2026
|
Q2 FY2026
Dec 31, 2025
|
Q1 FY2026
Sep 30, 2025
|
Q4 FY2025
Jun 30, 2025
|
Q3 FY2025
Mar 31, 2025
|
Q2 FY2025
Dec 31, 2024
|
Q1 FY2025
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
321
|
311
|
296
|
287
|
317
|
316
|
297
|
289
|
| Product And Services |
—
|
—
|
—
|
281
share 98.0%
|
—
|
—
|
—
|
—
|
| Consumables |
261
+3.1%
share 81.2%
|
257
-0.2%
share 82.6%
|
235
+2.0%
share 79.6%
|
232
+0.3%
share 80.8%
|
253
share 79.8%
|
258
share 81.5%
|
231
share 77.7%
|
231
share 79.8%
|
| Instruments |
32
+9.1%
share 9.8%
|
28
+5.9%
share 8.9%
|
30
-4.1%
share 10.0%
|
22
-16.7%
share 7.6%
|
29
share 9.1%
|
26
share 8.3%
|
31
share 10.4%
|
26
share 9.1%
|
| Services |
23
-22.1%
share 7.2%
|
21
-21.3%
share 6.9%
|
22
-18.4%
share 7.5%
|
—
|
30
share 9.3%
|
27
share 8.6%
|
27
share 9.2%
|
27
share 9.5%
|
| Royalty |
6
+6.5%
share 1.8%
|
5
-1.4%
share 1.6%
|
9
+5.1%
share 2.9%
|
6
+11.8%
share 2.0%
|
6
share 1.7%
|
5
share 1.6%
|
8
share 2.7%
|
5
share 1.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.